Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.32 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.32 |
| ▸ | CDK1 | P06493 | 2/20 | 0.32 |
| ▸ | CDK4 | P11802 | 2/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.32 |
| ▸ | CCND1 | P24385 | 2/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.32 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1694571 | 0.79 | CDK2 (0.33) | CDK2CCNB2CCNE2CDK1CDK4 | |
| SCHEMBL3467443 | 0.76 | CDK2 (0.31) | CDK2CCNB2CCNE2CDK1CDK4 | |
| SCHEMBL19684360 | 0.76 | — | — | |
| SCHEMBL3467464 | 0.72 | CDK2 (0.54) | CDK2CCNB2CCNE2CDK1CDK4 | |
| SCHEMBL19521626 | 0.70 | CDK2 (0.31) | CDK2CCNB2CCNE2CDK1CDK4 | |
| SCHEMBL7080405 | 0.69 | CDK2 (0.31) | CDK2 | |
| SCHEMBL7080407 | 0.67 | — | — | |
| SCHEMBL22545670 | 0.67 | — | — | |
| SCHEMBL22314882 | 0.64 | — | — | |
| SCHEMBL20858065 | 0.64 | CDK2 (0.34) | CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230008433-A1 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008433-A1 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | CDK2 2534/4885CCNB2 3409/4885CCNE2 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.